UPDATE ON INVESTMENT
01/11/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231101:nRSA9477Ra&default-theme=true
RNS Number : 9477R BioPharma Credit PLC 01 November 2023
1 November 2023
BIOPHARMA CREDIT PLC
UPDATE ON INVESTMENT
BioPharma Credit PLC (LSE: BPCR) notes the filing of a Form 6-K made on 1
November 2023 by LumiraDx Limited ("LumiraDx") which discloses an amendment
to the loan agreement entered into with BioPharma Credit PLC, BPCR Limited
Partnership, and BioPharma Credit Investments V (Master) LP, which is copied
below in part for convenience and can be found in its entirety at: LumiraDx
Form 6-K Report
(https://www.sec.gov/Archives/edgar/data/1685428/000095017023056948/form_6-k_pharma_amend_15.htm)
:
"EXPLANATORY NOTE
On October 31, 2023, LumiraDx Investment Limited, one of the subsidiaries of
LumiraDx Limited (the "Company"), entered into a fifteenth amendment to that
certain Loan Agreement, dated March 23, 2021 (as amended from time to time,
the "Loan Agreement"), with BioPharma Credit Investments V (Master) LP and
BPCR Limited Partnership, as lenders, and BioPharma Credit PLC, as collateral
agent (the "Fifteenth Amendment").
Pursuant to the Fifteenth Amendment, among other things, (i) the minimum
liquidity covenant in the Loan Agreement is waived until November 20, 2023,
provided that the consolidated liquidity of the Company and its subsidiaries
during this waiver period (and tested on a weekly basis) must be at least $5
million, (ii) the minimum net sales covenant for the trailing twelve-month
period ended September 30, 2023 will be tested on November 20, 2023, and (iii)
the lenders have agreed to provide, subject to the terms of the Loan Agreement
as amended by the Fifteenth Amendment, additional term loans to the Company,
in an aggregate amount of up to $8 million (the "New Term Loans"). The New
Term Loans will be subject to an interest rate of SOFR plus 8.0% per annum,
payable in quarterly installments. All amounts outstanding under the Loan
Agreement, including the New Term Loans, will mature on March 29, 2024.
The foregoing description of the Fifteenth Amendment does not purport to be
complete and is qualified in its entirety by reference to the Fifteenth
Amendment which is attached to this Form 6-K as Exhibit 4.1, and incorporated
herein by reference.
This report on Form 6-K, including Exhibit 4.1 hereto, shall be deemed to be
incorporated by reference into the Company's registration statements on Form
S-8 (File No. 333-259874, File No. 333-264611 and File No. 333-271538), and
the registration statements on Form F-3 (File No. 333-264609 and File No.
333-271624), and to be a part thereof from the date on which this report is
filed, to the extent not superseded by documents or reports subsequently
furnished."
Pharmakon Advisors, LP will continue to provide updates in due course.
Enquiries
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0) 20 7466 5000
biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)
Notes to Editors
BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END UPDMBBBTMTTJTMJ